We couldn't find that disease.
New imaging agent could sharpen view of HER2 cancers
NCT ID NCT06828588
First seen Oct 31, 2025
Summary
This early-phase study tests a radioactive tracer called [68Ga]Ga-ABY-025 for PET scans in 30 adults with advanced HER2-positive cancers (breast, stomach, head/neck, esophageal). Participants receive the tracer and a PET/CT scan while on standard HER2-targeted therapy. The main goal is to check safety and see if the tracer helps identify tumors better than current methods.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[68Ga]Ga-ABY-025 (a radioactive tracer for PET scans)
What this could lead to
If successful, this imaging method could help doctors more accurately spot HER2-positive tumors and monitor treatment response.
What could go wrong
This is a very early, small pilot study (30 people) focused on safety and imaging, not treatment. It may not lead to better outcomes or work for all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.